PHASE-II STUDY OF IFOSFAMIDE AND MESNA IN NONSQUAMOUS CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY

被引:26
作者
SUTTON, GP
BLESSING, JA
DISAIA, PJ
MCGUIRE, WP
机构
[1] INDIANA UNIV,SCH MED,GYNECOL ONCOL SECT,INDIANAPOLIS,IN 46202
[2] ROSWELL PK CANC INST,GYNECOL ONCOL GRP,BUFFALO,NY
[3] UNIV CALIF IRVINE,CTR CANC,DEPT OBSTET & GYNECOL,ORANGE,CA 92717
[4] JOHNS HOPKINS UNIV HOSP,CTR ONCOL,BALTIMORE,MD 21205
关键词
D O I
10.1006/gyno.1993.1084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A phase II trial of ifosfamide (IFX) and mesna was conducted by the GOG in patients with recurrent or advanced nonsquamous carcinoma of the cervix. A starting dose of 1.5 g/m2 IFX iv daily for 5 days and 300 mg/m2 mesna iv every 4 hr with three doses daily after IFX were given. In patients who had received prior radiotherapy or chemotherapy, the starting dose of IFX was reduced to 1.2 g/m2. Forty-six patients were entered, and 41 are evaluable for toxicity. Forty patients are evaluable for response. Age range was 30-72 yr. GOG performance status was 0-1 for all but 2 patients. Fifteen patients (37.5%) developed GOG grade 3 or 4 granulocytopenia, and 1 developed grade 4 thrombocytopenia. One patient developed transient renal insufficiency. There was one complete response and five partial responses (12.5%) for a response rate of 15.0%. Median response duration was 4.2 months (range, 1.7-22.6 months). Three responses were seen in areas with pelvic disease only. Three responses were observed in extrapelvic sites. IFX possesses activity which compares favorably with that of other agents in this disease. © 1993 by Academic Press, Inc.
引用
收藏
页码:48 / 50
页数:3
相关论文
共 16 条
[1]   AMINOTHIADIAZOLE (NSC-4728) IN PATIENTS WITH ADVANCED NONSQUAMOUS CARCINOMA OF THE CERVIX - A PHASE-II STUDY OF THE GYNECOLOGIC ONCOLOGY GROUP [J].
ASBURY, RF ;
BLESSING, JA ;
DISAIA, PJ ;
MALFETANO, J .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (05) :375-377
[2]  
BLESSING JA, 1984, CHEMOTHERAPY GYNECOL, P49
[3]   ICRF-159 (RAZOXANE) IN PATIENTS WITH ADVANCED NONSQUAMOUS CELL-CARCINOMA OF THE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY [J].
HOMESLEY, HD ;
BLESSING, JA ;
BERMAN, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (04) :325-326
[4]   COMBINATION CHEMOTHERAPY FOR METASTATIC OR RECURRENT ADENOCARCINOMA OF THE CERVIX [J].
KAVANAGH, JJ ;
GERSHENSON, D ;
COPELAND, L ;
ROBERTS, WS .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) :1621-1623
[5]  
KAVANAGH JJ, 1986, CANCER TREAT REP, V70, P923
[6]  
KAVANAGH JJ, 1987, CANCER TREAT REP, V71, P547
[7]   TENIPOSIDE (VM-26) IN PATIENTS WITH NON-SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A PHASE-II TRIAL OF THE GYNECOLOGIC ONCOLOGY GROUP [J].
MUSS, HB ;
BUNDY, BN ;
GIVEN, FT ;
STEHMAN, FB .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (02) :117-118
[8]  
MUSS HB, 1987, INVEST NEW DRUG, V5, P199
[9]  
SLAYTON RE, 1984, CANCER TREAT REP, V68, P1513
[10]  
SLAYTON RE, 1989, INVEST NEW DRUG, V7, P337